Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2017
DUBLIN, September 8, 2017 /PRNewswire/ --
The "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2017: Deal trends, players, financials and forecasts" report has been added to Research and Markets' offering.
The Global Cancer Monoclonal Antibody Partnering 2010-2017: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
The initial chapters of this report provide an orientation of Cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer monoclonal antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Cancer monoclonal antibody deals since 2010. Deals are listed by headline value, signed by big pharma, most active Cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of Cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits:
- In-depth understanding of cancer monoclonal antibody deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
- Comprehensive access to over 360 actual cancer monoclonal antibody deals entered into by the world's biopharma companies
- Identify most active companies in cancer monoclonal antibody partnering
- Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
- Spot the emerging companies in the cancer monoclonal antibody area
This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
- Monoclonal antibodies
- Murine mAb
- Chimeric mAb
- Humanized mAb
- Human aAb
The available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific oncology therapy target
- Monoclonal antibody type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Cancer monoclonal antibody dealmaking
Chapter 3 - Leading Cancer monoclonal antibody deals
Chapter 4 - Most active Cancer monoclonal antibody dealmakers
Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory
Chapter 6 - Cancer monoclonal antibody dealmaking by technology type
Chapter 7 - Partnering resource center
For more information about this report visit https://www.researchandmarkets.com/research/839ncd/global_cancer
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article